0001727689-25-000002.txt : 20250106 0001727689-25-000002.hdr.sgml : 20250106 20250106161117 ACCESSION NUMBER: 0001727689-25-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20250106 DATE AS OF CHANGE: 20250106 EFFECTIVENESS DATE: 20250106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Telo Genomics Corp. CENTRAL INDEX KEY: 0001872138 ORGANIZATION NAME: IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-534343 FILM NUMBER: 25511186 BUSINESS ADDRESS: STREET 1: 101 COLLEGE STREET, SUITE 200 CITY: TORONTO STATE: A6 ZIP: M5G 1L7 BUSINESS PHONE: 4166738487 MAIL ADDRESS: STREET 1: 101 COLLEGE STREET, SUITE 200 CITY: TORONTO STATE: A6 ZIP: M5G 1L7 D 1 primary_doc.xml X0708 D LIVE 0001872138 Telo Genomics Corp. 101 COLLEGE STREET, SUITE 200 TORONTO A6 ONTARIO, CANADA M5G 1L7 4166738487 CANADA (FEDERAL LEVEL) None None Corporation true Guido Baechler 101 College Street, Suite 200 Toronto A6 ONTARIO, CANADA M5G 1L7 Director Chairman Sabine Mai 101 College Street, Suite 200 Toronto A6 ONTARIO, CANADA M5G 1L7 Executive Officer Director Promoter Sherif Louis 101 College Street, Suite 200 Toronto A6 ONTARIO, CANADA M5G 1L7 Executive Officer Chris Ross 101 College Street, Suite 200 Toronto A6 ONTARIO, CANADA M5G 1L7 Executive Officer Hugh Rogers 101 College Street, Suite 200 Toronto A6 ONTARIO, CANADA M5G 1L7 Director Ron McGlennen 101 College Street, Suite 200 Toronto A6 ONTARIO, CANADA M5G 1L7 Director Biotechnology No Revenues 06b false 2024-12-23 true true true true true Units, each comprised of one common share and one common share purchase warrant. Each warrant has an exercise price of C$0.15 and a term of 36 months. false 0 26051 10420 15631 Dollar amounts have been converted from Canadian dollars based on the 0.6947 Bank of Canada daily exchange rate on 12-23-24. Total Remaining to be Sold represents the aggregate exercise price of warrants sold in the United States. false 1 0 0 0 true A portion of the net proceeds may be used for general working capital purposes, including for payments to officers and directors in the ordinary course, but proceeds are not earmarked for such payments false Telo Genomics Corp. /s/ Sherif Louis Sherif Louis President and CTO 2025-01-06